Shanghai Kaibao (300039): Performance is in line with expectations, new products will enter the early stages of listing
Shanghai Kaibao (300039) Quarterly Report Review: Performance is in line with expectations, and many products are in the early stages of listing
Shanghai Kaibao (300039): the performance meets the expectations and has a rich product line under research.
Shanghai Kaibao (300039) report comments: the performance is in line with the expected slowdown in the growth of the main products.
Shanghai Kaibao (300039): the performance forecast is in line with the expected echelon of new products.
Shanghai Kaibao (300039) Quarterly report comments: there is great pressure on short-and medium-term performance growth.
Depth * company * Shanghai Kaibao (300039) Annual report comments: stable performance growth looking forward to extension landing
[bank of China International Securities] Shanghai Kaibao: steady growth in performance, looking forward to the landing of extension
Comments on Shanghai Kaibao (300039) Annual report: the performance is in line with the expected product reserves
Shanghai Kaibao (300039): traditional Chinese medicine injection medical insurance pressure actively improve product structure
上海凯宝(300039):业绩增速回暖 内生外延共驱稳健成长
【东方证券】上海凯宝:业绩增速回暖,内生外延共驱稳健成长
上海凯宝(300039)季报点评:盈利增长逐季向好 产品梯队形成
上海凯宝(300039)中报点评:主打产品逐季恢复增长
上海凯宝(300039)年报点评:主打产品业绩承压 积极外延拓展产品线
上海凯宝(300039):参股肿瘤新药研发企业 助力中长期稳健增长 维持“增持”
【中泰证券】上海凯宝:参股肿瘤新药研发企业,助力中长期稳健增长,维持“增持”
上海凯宝(300039):招标寒冬下 中药针剂企业的徘徊 关注外延升级 维持“增持”
【中泰国际】上海凯宝:招标寒冬下,中药针剂企业的徘徊,关注外延升级,维持“增持”
上海凯宝(300039):主业经营相对平稳 外延值得期待
No Data